Short Interest in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Expands By 45.7%

ALX Oncology Holdings Inc. (NASDAQ:ALXO) was the recipient of a large growth in short interest in June. As of June 15th, there was short interest totalling 4,240,000 shares, a growth of 45.7% from the May 31st total of 2,910,000 shares. Approximately 14.2% of the shares of the company are sold short. Based on an average daily volume of 730,600 shares, the short-interest ratio is currently 5.8 days.

ALX Oncology Trading Up 3.3 %

ALXO stock opened at $6.03 on Monday. The firm has a market cap of $314.16 million, a PE ratio of -1.62 and a beta of 1.15. The firm has a fifty day moving average price of $12.02 and a 200 day moving average price of $13.23. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.21 and a current ratio of 5.21. ALX Oncology has a fifty-two week low of $3.94 and a fifty-two week high of $17.83.

ALX Oncology (NASDAQ:ALXO) last posted its earnings results on Thursday, May 9th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.16. Sell-side analysts anticipate that ALX Oncology will post -2.89 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on ALXO. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research note on Wednesday, May 29th. Stifel Nicolaus reissued a “hold” rating and issued a $14.00 target price (up previously from $10.00) on shares of ALX Oncology in a report on Friday, March 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of ALX Oncology in a research note on Monday, June 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, ALX Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $19.67.

Insider Transactions at ALX Oncology

In other ALX Oncology news, insider Jaume Pons sold 50,000 shares of the business’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $14.20, for a total transaction of $710,000.00. Following the completion of the sale, the insider now owns 604,205 shares of the company’s stock, valued at $8,579,711. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Sophia Randolph sold 12,000 shares of the company’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $15.94, for a total value of $191,280.00. Following the completion of the transaction, the insider now owns 330,349 shares of the company’s stock, valued at approximately $5,265,763.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jaume Pons sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $14.20, for a total value of $710,000.00. Following the sale, the insider now directly owns 604,205 shares in the company, valued at $8,579,711. The disclosure for this sale can be found here. Insiders sold 122,000 shares of company stock worth $1,611,280 in the last three months. Corporate insiders own 33.40% of the company’s stock.

Institutional Investors Weigh In On ALX Oncology

Institutional investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in ALX Oncology during the 4th quarter valued at $28,000. CANADA LIFE ASSURANCE Co bought a new position in ALX Oncology during the first quarter valued at $27,000. EntryPoint Capital LLC purchased a new stake in shares of ALX Oncology in the first quarter valued at $32,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of ALX Oncology by 66.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,587 shares of the company’s stock worth $107,000 after purchasing an additional 3,825 shares during the period. Finally, Barclays PLC grew its holdings in ALX Oncology by 57.1% during the 3rd quarter. Barclays PLC now owns 26,964 shares of the company’s stock valued at $129,000 after purchasing an additional 9,796 shares during the last quarter. 97.97% of the stock is owned by institutional investors.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.